Enliven Therapeutics, Inc. (ELVN)
ELVNNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$48.31
-2.88 (-5.63%) today
At the close, Nov 12, 4:00 PM ET. After hours $48.31 –
- Market cap
- $3.56bn
- P/E
- –
- EPS, last 4 quarters
- $-1.71
- Dividend yield
- –
- Day range
- $48.02 to $50.76
- 52-week range
- $14.79 to $62.32
- Average volume
- –
- Previous close
- $51.19
Analysts
11 coveringBuy11 buy, 0 hold, 0 sell
Targets a year out average $74.88, +55.0% from here
Earnings
next estimate $-0.4700Next report
Dec 2025
-14.3%
Mar 2026
+13.6%
Jun 2026
-28.9%
Sep 2026
+25.0%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$34.28m | -$27.82m | -$37.21m | -$36.05m |
| Net income | -$29.67m | -$23.63m | -$32.48m | -$27.70m |
News
8 latest- Enliven Appoints Former Antiva CEO Kristine Ball To Board As Relcobatinib Nears Phase 3 Launch RTTNews · Oct 15, 2026
- Enliven Gets FDA Alignment For Phase 3 Relcobatinib Trial In Blood Cancer RTTNews · Oct 7, 2026
- 5 Biotech Stocks That Delivered Big Gains - Key Catalysts Ahead For QURE, CDNA, ADPT, ELVN & AMLX RTTNews · Aug 2, 2026
- Biotech Stocks At 52-Week Highs- CDNA, IART, AGL, BVS, ELVN RTTNews · Jul 17, 2026
- What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130%The Motley Fool · Jun 27, 2026
- What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% RallyThe Motley Fool · Jun 27, 2026
- Medical Hedge Fund Sells 281,000 Shares of Enliven Theapeutics. Is it Time to Sell ELVN?The Motley Fool · Jun 24, 2026
- Top Biotech Gainers: SNSE Awaits Data In 2H, STTK To Begin Crohn's Trial In Q3, ALMS On Watch RTTNews · Jun 14, 2026
The company
Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision medicine approach that improves survival and enhances overall well-being. Enliven's discovery process combines deep insights into clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in Burlingame, California. To learn more, visit www.enliventherapeutics.com and connect with us on LinkedIn and X .
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- enliventherapeutics.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.